KDventures AB (STO:KDV), a Nordic investment company focused on life sciences, announced on Wednesday that its portfolio company AnaCardio AB has received US patent approval for AC01, its drug candidate for heart failure with reduced ejection fraction (HFrEF).
This patent extends intellectual property protection in the United States until June 2042, excluding potential term extensions.
AC01 demonstrated a favourable safety and tolerability profile in a Phase 2a clinical study completed in December 2025. The patent, co-owned by AnaCardio and Helsinn Healthcare SA, strengthens AC01's commercial potential and supports continued clinical development.
KDventures holds a 10% stake in AnaCardio.
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial